Stockholm, February 25, 2008

SCN Strengthens Cash Position to Meet Increased Demand on US Market

Scandinavian Clinical Nutrition is strengthening the company's cash position through bank financing due to increased demand on the US market.

In 2007/2008, SCN's product CUUR has been launched on the US market in accordance with the company's plans. The product is now being shipped to the major mass market chains, and it is also available in health food and specialty stores, in pharmacies and through direct marketing in radio and TV (Direct Response).

During 2007, SCN signed several important agreements for CUUR with leading partners such as Inverness Medical Innovations and Amway. These have now been implemented, and the results are starting to come in.

"We are now starting to see the results of our investments in CUUR, and especially DR is exceeding our expectations", says Ulf Söderberg, CEO of SCN.

More information:
Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81
Thomas Christensen, CFO, tc@scnutrition.com, +47 922 55 444

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina and Ledactin. Core competence and strategic alliances within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth on the international market. The shares of SCN are traded under the ticker "SCN" on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).